With the spin-off of Grail and Helix, and the addition of CEOs who are proficient in software, Illumina has begun to make genes a more important role in people's lives. This article, like a glimpse of the leopard, gives us a better look at the mysterious genetic sequencing company.
Despite the cost of research and development, this did not prevent Illumina's then-CEO Jay Flatley from continually dispensing his saliva and blood into bottles and sending them to the company's new lab. Since January 2009, Illumina scientists have embarked on their first mission – sequencing the entire human genome.
The project, dubbed "Jaynome", received prescriptions from Flatley's doctors to allow scientists to explore medical-related things. The laboratory spent weeks and tens of thousands of dollars to measure the genome sequence. Brad Sickler, a newly hired bioinformatics scientist at the time, recalled: “We feel pressured and many jobs are the first to try.†Jay is one of the top ten people in the world doing deep sequencing.
Jaynome's experimental results herald some potential and challenges – introducing gene sequencing into medical diagnostics. Flatley said he had a disease called "malignant hyperthermia" that caused the body to suddenly die under general anesthesia. "But if you understand it, 100% of the disease can be prevented," Flatley told us later. "But almost no one knows this." But Flatley knew this when he was young, otherwise he would not survive his childhood. At that time, there was no reliable data to compare, and it was not easy to extract from 3.5 to 4 million variants.
All in all, the Jaynome project set up by Flatley is on the road to “collecting popular genetic informationâ€, making the technology cheaper and better for the public. His company just played an important role in this regard.
.jpg)
A technician with a handheld sequencing instrument is working in front of a row of squeaky supercomputers in the company's internal lab.
If you have used 23andMe, Ancestry.com, or any other genetic testing service, chances are that your gene has been measured by a $25 billion biometric device. As the leader in DNA sequencing in the United States, Illumina has surpassed all its competitors by selling its genetic testing hardware to medical developers around the world.
Illumina contributed to reducing the cost of genetic testing from $100 million in 2001 to $1,000 today. "Nature" magazine once pointed out: "It not only surpassed Moore's Law, but also let the once crazy prophets hold their mouths." This process used to take weeks, but it can be done in a few days – the Illumina instrument (the HiSeq X Ten), which can be used by 16 people at a time, can complete a gene sequencing in just 3 days. After one year, this number reached 18,000.
With the growing knowledge of consumer genomics, the technology is rapidly moving from the laboratory to hospitals, clinics, and even families. Founded in 1998, Illumina is looking for ways to leverage the evolving clinical diagnostics and consumer markets with new applications and become an integral part of an entire DNA ecosystem.
Like other big companies, Illumina's challenge is to continue to innovate to maintain its core competencies. The company is currently opening a new chapter by announcing a series of "moon expedition" attempts: Helix and Grail. Helix and Grail will create an app store model (APP) for DNA information and pass early cancer screening results to each doctor's office. This summer, experienced Apple senior executive Phil Schiller joined the Illumina board of directors, which undoubtedly made the biotech company even more powerful in the consumer market.
“The opportunities that are now facing are exactly what the Internet encountered in the 1970s, exactly the same.â€
Surgical Tape,Adhesive Flexible Tape,Waterproof Surgical Tape,Breathable Surgicaltape
Zhende Medical Co.,Ltd , https://www.zhendemedicals.com